- You can view the full Biogen Idec Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Based on the negative study results, Lilly will not pursue regulatory approvals for solanezumab in Alzheimer's disease.